Welcome to our dedicated page for ASTRONICS SEC filings (Ticker: ATRO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ASTRONICS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ASTRONICS's regulatory disclosures and financial reporting.
Astronics Corporation filed a current report to note that on February 5, 2026 it issued a news release announcing preliminary unaudited adjusted EBITDA margins for the fourth quarter and full year of 2025. The company also highlighted plans to webcast its presentations at the TD Cowen Aerospace & Defense Conference.
BlackRock, Inc. has filed an amended Schedule 13G showing a significant passive stake in Astronics Corp common stock. As of 12/31/2025, BlackRock reports beneficial ownership of 2,749,452 shares, representing 8.7% of the outstanding common stock. BlackRock has sole voting power over 2,701,240 shares and sole dispositive power over all 2,749,452 shares, with no shared voting or dispositive power.
The filing states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Astronics. Various underlying clients have rights to dividends or sale proceeds, but no single client has more than five percent of Astronics’ outstanding common shares.
Astronics Corp’s major shareholder group 325 Capital and related reporting persons have amended their Schedule 13D to disclose that they no longer beneficially own any Astronics common stock. The amendment states that as of October 15, 2025, these reporting persons ceased to beneficially own more than 5% of Astronics’ outstanding shares. As of the latest referenced date, October 30, 2025, the company had 31,619,410 common shares outstanding. Each reporting person now reports beneficial ownership of 0 shares, representing 0% of the class, with no voting or dispositive power over Astronics stock.
Astronics Corporation filed a current report describing information shared at recent investor conferences. On January 13 and 14, 2026, the company presented preliminary revenue, bookings and backlog for the fourth quarter and full year 2025, along with its previously announced outlook for 2026. The presentation was also updated to add revenue expectations for Astronics’ Test segment within the 2026 outlook.
This updated investor presentation is attached as Exhibit 99.1 and is available on the company’s investor relations website. The company specifies that the information in this report and the exhibit is being furnished, not filed, which limits how it is treated under securities law.
Astronics Corporation filed a current report to note that it issued a news release with preliminary unaudited revenue and bookings for the fourth quarter of 2025, preliminary unaudited revenue for full year 2025, and initial revenue guidance for 2026. The detailed figures and outlook are contained in the attached press release, listed as Exhibit 99.1, which accompanies this report.
Astronics Corp insider Peter J. Gundermann, the company’s President, CEO and a director, reported a new grant of 29,750 stock options on December 4, 2025. The options have an exercise price of $51.72 per share, become exercisable on December 4, 2026, and expire on December 4, 2035, and relate to $.01 par value common stock.
After the reported transaction, he directly owned 83,906.608 shares of $.01 par value common stock and 747,911 shares of $.01 par value Class B stock. The filing also lists multiple existing option grants and restricted stock units, each RSU representing the right to receive one share of common stock at settlement. Several RSU awards for 9,206, 26,450 and 25,250 shares may vest in 2026, 2027 and 2028 based on Astronics’ average annual adjusted EBITDA over the periods January 1, 2023–December 31, 2025, January 1, 2024–December 31, 2026, and January 1, 2025–December 31, 2027, with vesting ranges between 75% and 115% or between 50% and 150% of target depending on the grant.
Astronics Corp executive James Mulato, President of Astronics Test Systems, reported a stock transaction and updated his equity holdings. On 12/01/2025, he sold 9,734 shares of $.01 par value common stock at $53.24 per share. After this sale, he directly holds 27,077.822 shares of common stock and 2,453 shares of Class B stock.
He also reports a broad set of stock options on Astronics common and Class B stock, with exercise prices ranging from $9.74 to $35.61 and expiration dates from 2026 through 2033. In addition, he holds performance-based restricted stock units (RSUs): 18,550 units tied to average annual adjusted EBITDA for 2024–2026 that may vest between 50% and 150% of target on February 22, 2027; 11,500 units tied to EBITDA for 2023–2025 that may vest between 75% and 115% on February 23, 2026; and 17,700 units tied to EBITDA for 2025–2027 that may vest between 50% and 150% on February 27, 2028, all based on actual performance.
Astronics Corp (ATRO) reported insider equity activity by its President and CEO, who is also a director. On 11/20/2025, he exercised stock options for 13,700 shares of $.01 par value common stock and 4,418 shares of $.01 par value Class B stock at an exercise price of $27.72 per share. To cover withholding taxes from the option exercise, 11,707 common shares were withheld at a price of $49.35 per share. Following these transactions, he beneficially owned 83,906.608 shares of common stock and 747,911 shares of Class B stock directly. The filing also lists multiple remaining stock option grants and restricted stock units that vest over future years based on Astronics’ average annual adjusted EBITDA performance metrics, with potential vesting between 50% and 150% of target. This Form 4 clarifies that these transactions are being reported on an original filing rather than an amendment.
Astronics Corp. (ATRO) President and CEO Peter J. Gundermann reported multiple equity transactions dated 11/20/2025. He exercised stock options to acquire 13,700 shares of $.01 par value common stock and 4,418 shares of $.01 par value Class B stock at an exercise price of $27.72 per share. To cover withholding taxes tied to the option exercise, 11,707 common shares were withheld at a price of $49.35 per share. Following these transactions, he directly owned 83,906.608 common shares and 747,911 Class B shares.
The filing also lists outstanding equity awards. These include multiple stock option grants with exercise prices ranging from $9.74 to $35.61 per share and expirations between 12/03/2025 and 12/07/2033, as well as several restricted stock unit awards tied to Astronics’ average annual adjusted EBITDA performance for periods running from 2023–2027, with potential vesting ranges between 50% and 150% of target on future dates.
Astronics Corp (ATRO) Executive VP & President–Aerospace Mark Peabody reported exercising stock options and acquiring company shares. On 11/19/2025, he exercised options to acquire 4,500 shares of $.01 par value common stock at $27.72 per share and 1,451 shares of $.01 par value Class B stock at $27.72 per share. Following these transactions, he beneficially owned 55,324.73 common shares and 185,445 Class B shares directly.
The filing also lists multiple option grants and restricted stock units. Several RSU awards vest based on Astronics’ average annual adjusted EBITDA over multi‑year periods ending December 31, 2025, December 31, 2026, and December 31, 2027, with between 50% and 150% (or 75% to 115% for one grant) of target units eligible to vest in February 2026, February 2027, and February 2028 based on actual performance.